ERBB2 and breast carcinoma: Due to considering HER2 as a therapeutic target for breast cancer and advances in HER2-targeted therapy, the prognosis of patients with HER2-positive breast cancer has been changed, and with improved anti-HER2-targeted therapy, patient survival time has significantly increased (8,9).